Skip to main content

CORRECTION article

Front. Immunol., 02 March 2018
Sec. Cancer Immunity and Immunotherapy
Volume 9 - 2018 | https://doi.org/10.3389/fimmu.2018.00403

Corrigendum: Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study

This article is a correction to:

  1. Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study

    1. Read original article
\r\nPaola QueiroloPaola Queirolo1Beatrice DozinBeatrice Dozin2Anna MorabitoAnna Morabito3Barbara Banelli,Barbara Banelli3,4Patrizia PiccioliPatrizia Piccioli5Cristiana FavaCristiana Fava1Claudio LeoClaudio Leo1Roberta CarosioRoberta Carosio3Stefania LaurentStefania Laurent6Vincenzo FontanaVincenzo Fontana2Pier Francesco FerrucciPier Francesco Ferrucci7Chiara MartinoliChiara Martinoli7Emilia CocorocchioEmilia Cocorocchio7Angelo BattagliaAngelo Battaglia7Paolo A. AsciertoPaolo A. Ascierto8Mariaelena CaponeMariaelena Capone8Ester SimeoneEster Simeone8Federica De GalitiisFederica De Galitiis9Elena PaganiElena Pagani9Gian Carlo Antonini CappelliniGian Carlo Antonini Cappellini9Paolo Marchetti,Paolo Marchetti9,10Michele GuidaMichele Guida11Stefania TommasiStefania Tommasi11Mario MandalMario Mandalà12Barbara MerelliBarbara Merelli12Pietro QuaglinoPietro Quaglino13Paolo FavaPaolo Fava13Massimo GuidoboniMassimo Guidoboni14Massimo RomaniMassimo Romani3Francesco SpagnoloFrancesco Spagnolo1and and \r\nMaria Pia Pistillo* On Behalf of the Italian Melanoma Intergroup (IMI)\r\nMaria Pia Pistillo3* On Behalf of the Italian Melanoma Intergroup (IMI)
  • 1Department of Medical Oncology, IRCCS AOU San Martino-IST-Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy
  • 2Unit of Clinical Epidemiology, IRCCS AOU San Martino-IST-Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy
  • 3Unit of Tumor Epigenetics, IRCCS AOU San Martino-IST-Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy
  • 4Department of Health Sciences, University of Genova, Genova, Italy
  • 5Unit of Cellular Biology, IRCCS AOU San Martino-IST-Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy
  • 6Intergruppo Melanoma Italiano (IMI) and Department of Internal Medicine, University of Genova, Genova, Italy
  • 7Oncology of Melanoma Unit, European Institute of Oncology, Milan, Italy
  • 8Melanoma, Cancer Immunotherapy and Innovative Therapy Unit, Istituto Nazionale Tumori Fondazione ‘G. Pascale’, Naples, Italy
  • 9Istituto Dermopatico dell’Immacolata IDI-IRCCS, Rome, Italy
  • 10Medical Oncology, Sant’Andrea Hospital, Sapienza University of Rome, Rome, Italy
  • 11Department of Medical Oncology, Molecular Genetics Laboratory, IRCCS Istituto Tumori “Giovanni Paolo II,” Bari, Italy
  • 12Unit of Medical Oncology, Department of Oncology and Hematology, Papa Giovanni XXIII Hospital, Bergamo, Italy
  • 13Dermatologic Clinic, Department of Medical Sciences, University of Turin, Turin, Italy
  • 14Immunotherapy and Cell Therapy, IRCCS-IRST, Meldola, Italy

A corrigendum on

Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study
by Queirolo P, Dozin B, Morabito A, Banelli B, Piccioli P, Fava C, et al. Front Immunol (2017) 8:386. doi: 10.3389/fimmu.2017.00386

In the original article, affiliation number 9 was wrong. The correct affiliation 9 is “Istituto Dermopatico dell’Immacolata IDI-IRCCS, Rome, Italy”. This error does not change the scientific conclusions of the article in any way.

The original article has been updated.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Keywords: CTLA-4 variants, melanoma, ipilimumab, best overall response, overall survival, predictive/prognostic factor

Citation: Queirolo P, Dozin B, Morabito A, Banelli B, Piccioli P, Fava C, Leo C, Carosio R, Laurent S, Fontana V, Ferrucci PF, Martinoli C, Cocorocchio E, Battaglia A, Ascierto PA, Capone M, Simeone E, De Galitiis F, Pagani E, Antonini Cappellini GC, Marchetti P, Guida M, Tommasi S, Mandalà M, Merelli B, Quaglino P, Fava P, Guidoboni M, Romani M, Spagnolo F, and Pistillo MP (2018) Corrigendum: Association of CTLA-4 Gene Variants with Response to Therapy and Long-term Survival in Metastatic Melanoma Patients Treated with Ipilimumab: An Italian Melanoma Intergroup Study. Front. Immunol. 9:403. doi: 10.3389/fimmu.2018.00403

Received: 15 January 2018; Accepted: 13 February 2018;
Published: 02 March 2018

Edited and Reviewed by: Matteo Bellone, San Raffaele Hospital (IRCCS), Italy

Copyright: © 2018 Queirolo, Dozin, Morabito, Banelli, Piccioli, Fava, Leo, Carosio, Laurent, Fontana, Ferrucci, Martinoli, Cocorocchio, Battaglia, Ascierto, Capone, Simeone, De Galitiis, Pagani, Antonini Cappellini, Marchetti, Guida, Tommasi, Mandalà, Merelli, Quaglino, Fava, Guidoboni, Romani, Spagnolo and Pistillo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Maria Pia Pistillo, mariapia.pistillo@hsanmartino.it

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.